Hematopoietic stem cell

Sierra Space and BioServe Space Technologies to Demonstrate In-Space Stem Cell Production to Better Treat Cancer Patients on Earth

Retrieved on: 
Wednesday, August 2, 2023
Research, Technology, Other Technology, Aerospace, Stem Cells, Manufacturing, Biotechnology, Health, Science, Oncology, Lymphoma, BioServe Space Technologies, University of Colorado Boulder, Sierra Nevada Corporation, ISS National Lab, Mayo Clinic, University, Industrial Revolution, Hematopoietic stem cell, Orbit, Dream, Bone marrow, Commercial Resupply Services, International Space Station, Multimedia, Cell, Stem cell, Pathfinder, Patient, Risk, Blood, LEO, Dream Chaser, Multiple myeloma, Clinical professor, Longevity, Scientific research on the International Space Station, Leukemia, ISS, Mobile phone, Communications satellite

View the full release here: https://www.businesswire.com/news/home/20230802178510/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230802178510/en/
    For the in-space experiment, Sierra Space, BioServe and the study team sent stem cell samples from multiple umbilical cord blood donors to look for beneficial differences during the cell growth experiment.
  • However, stem cell transplants require large numbers of cells to be effective, and it is challenging to grow cord blood stem cells to produce enough for effective treatment.
  • When grown on Earth, hematopoietic stem cells normally change into dedicated blood cell lines, which is not optimal for patient recovery.
  • The stem cell samples will be frozen at different time points while in orbit and sent back to Earth for analysis.

CHOP and Penn Medicine Researchers Develop "In Vivo" RNA-based Gene Editing Model for Blood Disorders

Retrieved on: 
Thursday, July 27, 2023
Nanoparticle, Bone marrow, Doctor of Philosophy, Bangladesh Technical Education Board, COVID-19 vaccine, MD, Patient, Division, Risk, Thomas, Perelman School of Medicine at the University of Pennsylvania, LNP Media Group, CD117, DSM-IV codes, Infection, Disease, Children's Hospital of Philadelphia, Tissue, Hematologic disease, BS, University, Pediatrics, Therapy, CHOP, Hematology, Gene editing, Biomedical Research, Mutation, Research, Penn Institute for Urban Research, DOI, Hospital, HSC, NIH, Vaccine, Hematopoietic stem cell, Stem cell, COVID-19, Philadelphia, Cell, Child, Antibody, Messenger, Blood, Immune system, LNP, Radiation, Doctor of Pharmacy, Cell death, PUMA, SCID, Sickle cell disease, RNA, Penn, Health, Dicarboxylic acid, Dentistry, Pharmaceutical industry, Science

PHILADELPHIA, July 27, 2023 /PRNewswire/ -- In a step forward in the development of genetic medicines, researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders, allowing for the modification of diseased blood cells directly within the body. If translated into the clinic, this approach could expand access and reduce the cost of gene therapies for blood disorders, many of which currently require patients receive chemotherapy and a stem cell transplant. The findings were published today in the journal Science.

Key Points: 
  • This approach could expand access and reduce the cost of gene therapies for blood disorders.
  • A targeted mRNA-encoded genomic editing methodology could lead to controlled expression, high editing efficacy, and potentially safer in vivo genomic modification compared to currently available technologies."
  • In patients with non-malignant hematopoietic disorders like sickle cell disease and immunodeficiency disorders, these blood cells don't function correctly because they carry a genetic mutation.
  • First, the researchers tested CD117/LNP encapsulating reporter mRNA to show successful in vivo mRNA expression and gene editing.

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Retrieved on: 
Wednesday, April 27, 2022
Biotechnology, Health, Clinical Trials, Cardiology, Oncology, UCB, HSCT, Transplant, Poster, Duke Cancer Institute, Aplastic anemia, U.S. Securities and Exchange Commission, COVID-19, Lymphatic system, Twitter, Security (finance), Infection, Private Securities Litigation Reform Act, Therapy, Risk, OS, Patient, Cell, LinkedIn, Trial of the century, Mortality, Technology, Phenotype, SEC, TCT, Safety, Instagram, NK, Hematopoietic stem cell, NAM, Facebook, FDA, BLA, UCBT, Hematology, B cell, Graft-versus-host disease, Cancer, Pharmaceutical industry, Vaccine

The data showed sustained clinical benefits in the first-year post-transplant with omidubicel, as demonstrated by significant reduction in infectious complications.

Key Points: 
  • The data showed sustained clinical benefits in the first-year post-transplant with omidubicel, as demonstrated by significant reduction in infectious complications.
  • There was a continued trend toward improved OS in favor of the omidubicel arm over time (73% vs. 60%).
  • The overall and sustained clinical benefit of omidubicel makes it an important addition to the options for allogeneic HSCT.
  • For additional information on Gamida Cell, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn , Twitter , Facebook or Instagram at @GamidaCellTx.

Stem Cell Manufacturing Market - 42% of Growth to Originate from North America| Evolving opportunities with Becton Dickinson and Co. & Bio Techne Corp.| 17000+ Technavio Reports

Retrieved on: 
Monday, February 21, 2022
Deployment, Potency (pharmacology), Merck Group, SC, Growth, HSCT, Hematopoietic stem cell, Corning Inc., Prevalence, Investment, Mimesis, ROW, BC, Danaher Corporation, PerkinElmer, Stem cell, Sartorius AG, Asp, ECM, USD, TB, Research report, Biotechnology, C, Thermo Fisher Scientific, Geography, Enumeration, AI, Merck, CAGR, CRO, BD (company), Fine chemical, Music

Becton Dickinson and Co. -The company offers stem cell manufacturing kits namely a stem cell Enumeration kit.

Key Points: 
  • Becton Dickinson and Co. -The company offers stem cell manufacturing kits namely a stem cell Enumeration kit.
  • Bio-Techne Corp. -The company offers stem cell manufacturing solutions such as induced Pluripotent Stem Cells, Hematopoietic stem cells among others.
  • Lonza Group Ltd. -The company offers a stem cell manufacturing kit namely a Mesenchymal stem cell growth medium bullet kit.
  • The competitive scenario provided in the stem cell manufacturing market report analyzes, evaluates, and positions companies based on various performance indicators.

Rheos Medicines Forms Research Collaboration With CRYOSTEM to Evaluate MALT1‑Targeted Therapeutics for Graft-versus-Host-Disease

Retrieved on: 
Wednesday, October 27, 2021
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Research, Diagnosis, Inflammation, University, LinkedIn, HSCT, Immunosuppression, GVHD, Third Rock Ventures, MALT1, Patient, Hematopoietic stem cell transplantation, T helper cell, Hematopoietic stem cell, Precision medicine, Biological Resource Center, Collection, Transplant, Disease, Multimedia, National Cancer Institute, Mortality, Immune system, Mark (given name), Therapy, Autoimmunity, Investor, Pharmaceutical industry, Vaccine, MALT1, CRYOSTEM, Rheos Medicines, MALT1, CRYOSTEM, RHEOS MEDICINES

Rheos Medicines , a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory disease, today announced a research collaboration with the French non-profit research organization CRYOSTEM.

Key Points: 
  • Rheos Medicines , a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory disease, today announced a research collaboration with the French non-profit research organization CRYOSTEM.
  • Under the terms of the research collaboration, CRYOSTEM will provide Rheos with biological resources for post-transplant patients in three categories: those who developed acute GvHD, those who developed chronic GVHD, and those who did not develop GvHD.
  • Since 2015, CRYOSTEM has provided the national and international scientific community with these samples for large-scale research to improve the knowledge of HSCT complications.
  • Rheos Medicines is a biopharmaceutical company developing novel, small molecule medicines to treat autoimmune and inflammatory diseases with greater precision by targeting the metabolic hubs of the immune system.

Global Hematopoietic Stem Cell Transplantation Market to 2027 - Size, Share, Outlook, and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Health, Stem cells, Branches of biology, Medical specialties, Biology, Stem cells, Hematology, Transplantation medicine, Surgical oncology, Lymphology, Hematopoietic stem cell transplantation, Hematopoietic stem cell, Bone marrow, HSCT

The "Hematopoietic Stem Cell Transplantation (HSCT) Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hematopoietic Stem Cell Transplantation (HSCT) Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global hematopoietic stem cell transplantation market is expected to witness significant growth during the forecast period owing to the increasing prevalence of leukemia and lymphoma.
  • Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow, or umbilical cord blood are transplanted into the patient.
  • Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis.

Anthology Welcomes Dr. Melissa Harts as Chief People Officer

Retrieved on: 
Monday, August 2, 2021
Harts

BOCA RATON, Fla., Aug. 2, 2021 /PRNewswire-PRWeb/ -- Anthology, a leading provider of proven higher education solutions that support the entire learner lifecycle, has named Dr. Melissa Harts as Anthology's Chief People Officer.

Key Points: 
  • BOCA RATON, Fla., Aug. 2, 2021 /PRNewswire-PRWeb/ -- Anthology, a leading provider of proven higher education solutions that support the entire learner lifecycle, has named Dr. Melissa Harts as Anthology's Chief People Officer.
  • "I've had the privilege of collaborating with Dr. Harts during the selection process and the implementation of our Anthology solutions at PHSC.
  • I am constantly impressed with her passion for people and ability to lead teams with empathy and resiliency," said Jim Milton, Chairman and Chief Executive Officer of Anthology.
  • "I know firsthand how dedicated the team at Anthology is to helping higher education institutions advance and thrive," said Dr. Harts.

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Biology, Medical specialties, Stem cells, Biotechnology, Immune system, Lymphocytes, Natural killer cell, Hematopoietic stem cell, Myelodysplastic syndrome, Clonal hypereosinophilia

MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.

Key Points: 
  • MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.
  • Current treatments, including chemotherapy and bone marrow/stem cell transplantation, have varying degrees of success, and there is no known cure for MDS.
  • In the lab we have shown that INKmune binds to multiple NK receptors and initiates the activation of over 3000 genes associated with function, trafficking, proliferation and survival.
  • No single cytokine in our hands has such broad, physiological effects, which has inspired us to refer to INKmune as a pseudokine.

PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

Retrieved on: 
Friday, July 9, 2021
Research, Stem cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Biology, Stem cells, Blood cells, Cell biology, Cancer immunotherapy, Biotechnology, Cell therapy, Acute myeloid leukemia, Immunotherapy, Hematopoietic stem cell, Haematopoiesis, Vor Biopharma, PureTech Health, VOR BIOPHARMA, PURETECH HEALTH

The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.

Key Points: 
  • The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.
  • We believe this unique combination will leverage each technologys strengths, while protecting patients against off-target effects of these powerful immunotherapies.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • Forward-looking statements in this press release include the Companys statements regarding its platforms potential to treat patients suffering from acute myeloid leukemia.

Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant

Retrieved on: 
Wednesday, June 23, 2021
Science, Radiology, Research, Oncology, Health, FDA, Clinical trials, Other Health, Branches of biology, Medical specialties, Stem cells, Biology, Cell therapy, Hematopoietic stem cell transplantation, Hematopoietic stem cell, Tumors of the hematopoietic and lymphoid tissues, Bone marrow, Guo Mei, Graft-versus-tumor effect, Omidubicel, Gamida Cell, OMIDUBICEL, GAMIDA CELL

Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell transplant solution for patients with hematologic malignancies.

Key Points: 
  • Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell transplant solution for patients with hematologic malignancies.
  • The robust results of this clinical trial have demonstrated that omidubicel could provide an important new option for patients with hematologic malignancies in need of a bone marrow transplant.
  • Previous studies have shown that engraftment with omidubicel is durable, with some patients in the Phase 1/2 study now a decade past their transplant.
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.